Skip to main content
. Author manuscript; available in PMC: 2019 Jun 21.
Published in final edited form as: Leuk Lymphoma. 2012 Sep 8;54(1):167–173. doi: 10.3109/10428194.2012.708026

Figure 4. Induction of NK Degranulation with Primary ALL Blasts.

Figure 4

A) Induction of NK degranulation by 10 primary ALL samples (1-10) treated with 50nM Bortezomib (B), 1mM Valproate (V), 5μM Troglitazone (T) or vehicle control for 16 hours. Fold change in % specific degranulation = the ratio of % specific degranulation with and without drug.

B-D) Cumulative analysis of data in A) shown for each drug treatment (shaded bars) compared with untreated controls (open bars).

E-G) NK degranulation against 3 primary ALL samples treated as above, with 20µM src kinase inhibitor PP2 (shaded bars) vs no kinase inhibitor (open bars): D) 50nM Bortezomib, E) 1mM Valproate, F) 5μM Troglitazone (*p<0.05, **p<0.01).